OpenResearchAlpha

European Heart Journal - Cardiovascular Pharmacotherapy · 11 Nov 2026

Impact of beta-blockers on quality of life in patients with myocardial infarction without heart failure: A prespecified substudy of the DANBLOCK trial

Frida Rykind-Eriksenh-index 0, Anna Meta Dyrvig Kristensen, Therese Holmager, Harun Caglar, Johanne E Nyen, Ann-Dorthe Zwisler, Jess Lambrechtsen, Svend E Jensen, John Munkhaugen, Eva Prescotth-index 76

0
Citations
no database records one yet
0
Citations in 2026
so far
76
Leading author's h-index
Eva Prescott, in QAI's scholar index
0
References
works it cites, from open citation data

Citations by database

Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.

  • OpenCitations0
  • Crossref0
  • Europe PMC0

Citations per year

The current year is still counting.

  • 2026 so far0

Abstract

Abstract Background and Aims Contemporary evidence on the effects of beta-blockers on health-related quality of life (HRQoL) after myocardial infarction (MI) in patients without heart failure is limited, despite widespread use. In this prespecified substudy of the DANBLOCK trial, we aimed to assess whether beta-blocker therapy influences HRQoL after MI in patients with left ventricular ejection fraction (LVEF) >40%. Methods Patients with a recent (≤14 days) MI and LVEF >40% were randomised to open-label beta-blocker therapy or no beta-blocker. HRQoL was assessed at baseline and at three-, 12-, and 24-months using the EQ-5D-5L questionnaire and the EQ visual analogue scale (EQ VAS). The primary endpoints were between-group differences in change from baseline to each follow-up visit estimated by a linear mixed-effects model. Results Among 2707 randomised patients, 2681 (99%) completed at least one EQ-5D-5L questionnaire. Median EQ-5D and EQ VAS scores at baseline were 0.95 (Interquartile range [IQR]: 0.87-1.00) and 77 (IQR: 65-87), respectively. Scores remained stable throughout follow-up. No significant between-group differences for EQ-5D index score and EQ VAS score were observed at any time point. At 12 months, mean difference (beta-blocker minus no beta-blocker) in EQ-5D index- and EQ VAS score was -0.001 (95% confidence interval [CI], -0.016 to 0.013, P=0.86) and -1.35 (95% CI, -2.85 to 0.15, P=0.08), respectively. Results were consistent in prespecified subgroups (age, sex, type of MI, and LVEF). Conclusion Overall, a high HRQoL was observed among post-MI patients. Beta-blocker therapy did not affect HRQoL after MI in patients without heart failure.

What the data shows

  • No database records a citation yet, as is usual for a paper this new.
  • Eva Prescott has the highest h-index among the authors (76).

Graph

This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.

Citing paper shares an authorAuthor without a profileSize shows citations, or h-index for authors

Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.

Start with

Authors (10)

Each author's standing in QAI's scholar index: the works their ORCID iD is attached to, and for anyone whose ORCID record names a lab OpenResearch follows, their arXiv preprints matched by name and a shared co-author. Names are as printed on the paper.

ProfileMost-cited paper

Cited by 0 papers

Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.

0 shown
No citing papers for this filter.

References (0)

What it cites, from open citation data, with Crossref's record of each.

No references in the open citation data yet.
Impact of beta-blockers on quality of life in patients with myocardial infarction without heart failure: A prespecified substudy of the DANBLOCK trial - QAI OpenResearch